Patents by Inventor Timo Kars van den Berg
Timo Kars van den Berg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11718681Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.Type: GrantFiled: February 2, 2022Date of Patent: August 8, 2023Assignee: Byondis B.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
-
Publication number: 20220195063Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.Type: ApplicationFiled: February 2, 2022Publication date: June 23, 2022Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE
-
Patent number: 11274159Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.Type: GrantFiled: May 15, 2018Date of Patent: March 15, 2022Assignee: Byondis B.V.Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
-
Publication number: 20210206852Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: March 18, 2021Publication date: July 8, 2021Inventor: Timo Kars VAN DEN BERG
-
Patent number: 10981988Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: February 6, 2018Date of Patent: April 20, 2021Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars Van Den Berg
-
Publication number: 20210070874Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.Type: ApplicationFiled: May 15, 2018Publication date: March 11, 2021Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE
-
Patent number: 10287351Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: June 9, 2017Date of Patent: May 14, 2019Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars Van Den Berg
-
Publication number: 20180155424Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: February 6, 2018Publication date: June 7, 2018Inventor: Timo Kars VAN DEN BERG
-
Patent number: 9920122Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: May 3, 2016Date of Patent: March 20, 2018Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars van den Berg
-
Patent number: 9790275Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: October 28, 2016Date of Patent: October 17, 2017Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars Van Den Berg
-
Publication number: 20170275364Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: June 9, 2017Publication date: September 28, 2017Inventor: Timo Kars VAN DEN BERG
-
Publication number: 20170044258Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: October 28, 2016Publication date: February 16, 2017Inventor: Timo Kars VAN DEN BERG
-
Publication number: 20160244522Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: May 3, 2016Publication date: August 25, 2016Inventor: Timo Kars van den Berg
-
Patent number: 9352037Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: January 13, 2014Date of Patent: May 31, 2016Assignee: STICHTING SANQUIN BLOEDVOORZIENINGInventor: Timo Kars van den Berg
-
Publication number: 20140199308Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: January 13, 2014Publication date: July 17, 2014Applicant: STICHTING SANQUIN BLOEDVOORZIENINGInventor: Timo Kars van den Berg
-
Patent number: 8728476Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: GrantFiled: April 23, 2009Date of Patent: May 20, 2014Assignee: Stichting Sanquin BloedvoorzieningInventor: Timo Kars van den Berg
-
Publication number: 20110038870Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.Type: ApplicationFiled: April 23, 2009Publication date: February 17, 2011Inventor: Timo Kars van den Berg
-
Publication number: 20020114807Abstract: The invention relates to a method for inhibiting cell functioning for use in anti-inflammatory and anti-tumor therapies in the body of a warm-blooded living being, which comprises administering to said being a drug comprising, in a quantity effective for said therapies, a substance that specifically recognizes the extracellular domain of SIRP (anti-SIRP substance) and that inhibits the functioning of pathologic myeloid cells. The invention further relates to a drug to be used in the above method and to the active substance of said drug.Type: ApplicationFiled: October 26, 2001Publication date: August 22, 2002Inventors: Timo Kars van den Berg, Christine Diederike Dijkstra